International Clinical Trial: Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815626) titled 'Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Zhongshan Sansure Hygene Biomedicine Co., Ltd.

Condition: Idiopathic Short Stature (ISS)

Intervention: Drug: Human Growth Hormone (hGH)

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: September 2026

Target Sample Size: 240

Count...